Klinische utiliteit van comprehensive genomic profiling: van bewijsgeneratie naar duurzame toegang

The GeNeo study (REF-EJC-Aftimos) provides timely real-world data on the contribution of comprehensive genomic profiling (CGP) in oncology practice. By increasing the detection of actionable alterations and access to matched targeted therapies, it adds important evidence in a rapidly evolving but still challenging field. Advances in next-generation sequencing (NGS) have transformed precision oncology, with large NGS panels expanding molecular characterization beyond single-gene or small-panel testing.